T1	Participants 60 91	anti-herpes virus therapy in MS
T2	Participants 204 253	patients with relapsing-remitting MS in a phase 2
T3	Participants 443 558	Patients were eligible for the study if they had had two or more MS relapses in the 2-year period before enrollment
T4	Participants 560 633	Seventy patients with Expanded Disability Status Scale scores of 0 to 5.5
T5	Participants 1892 1991	patients with relapsing-remitting MS who had two or more relapses during the previous 2-year period
T6	Participants 2397 2461	patients with MS and high levels of MRI-evident disease activity
